Lauren M Hurwitz1, Jennifer Cullen2, Sally Elsamanoudi3, Daniel J Kim4, Jane Hudak4, Maryellen Colston4, Judith Travis4, Huai-Ching Kuo1, Christopher R Porter5, Inger L Rosner6. 1. Department of Defense, Center for Prostate Disease Research, Rockville, MD; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD. 2. Department of Defense, Center for Prostate Disease Research, Rockville, MD; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD. 3. Department of Defense, Center for Prostate Disease Research, Rockville, MD; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Department of Urology, Walter Reed National Military Medical Center, Bethesda, MD. 4. Department of Urology, Walter Reed National Military Medical Center, Bethesda, MD. 5. Department of Defense, Center for Prostate Disease Research, Rockville, MD; Department of Urology, Virginia Mason Medical Center, Seattle, WA. 6. Department of Defense, Center for Prostate Disease Research, Rockville, MD; Department of Urology, Walter Reed National Military Medical Center, Bethesda, MD. Electronic address: inger.l.rosner.mil@mail.mil.
Abstract
BACKGROUND: Patients diagnosed with prostate cancer (PCa) are presented with several treatment options of similar efficacy but varying side effects. Understanding how and why patients make their treatment decisions, as well as the effect of treatment choice on long-term outcomes, is critical to ensuring effective, patient-centered care. This study examined treatment decision-making in a racially diverse, equal-access, contemporary cohort of patients with PCa counseled on treatment options at a multidisciplinary clinic. METHODS: A prospective cohort study was initiated at the Walter Reed National Military Medical Center (formerly Walter Reed Army Medical Center) in 2006. Newly diagnosed patients with PCa were enrolled before attending a multidisciplinary clinic. Patients completed surveys preclinic and postclinic to assess treatment preferences, reasons for treatment choice, and decisional regret. RESULTS: As of January 2014, 925 patients with PCa enrolled in this study. Surgery (54%), external radiation (20%), and active surveillance (12%) were the most common primary treatments for patients with low- and intermediate-risk PCa, whereas patients with high-risk PCa chose surgery (34%) or external radiation with neoadjuvant hormones (57%). Treatment choice differed by age at diagnosis, race, comorbidity status, and calendar year in both univariable and multivariable analyses. Patients preferred to play an active role in the decision-making process and cited doctors at the clinic as the most helpful source of treatment-related information. Almost all patients reported satisfaction with their decision. CONCLUSIONS: This is one of the first prospective cohort studies to examine treatment decision-making in an equal-access, multidisciplinary clinic setting. Studies of this cohort would aid in understanding and improving the PCa decision-making process. Published by Elsevier Inc.
BACKGROUND:Patients diagnosed with prostate cancer (PCa) are presented with several treatment options of similar efficacy but varying side effects. Understanding how and why patients make their treatment decisions, as well as the effect of treatment choice on long-term outcomes, is critical to ensuring effective, patient-centered care. This study examined treatment decision-making in a racially diverse, equal-access, contemporary cohort of patients with PCa counseled on treatment options at a multidisciplinary clinic. METHODS: A prospective cohort study was initiated at the Walter Reed National Military Medical Center (formerly Walter Reed Army Medical Center) in 2006. Newly diagnosed patients with PCa were enrolled before attending a multidisciplinary clinic. Patients completed surveys preclinic and postclinic to assess treatment preferences, reasons for treatment choice, and decisional regret. RESULTS: As of January 2014, 925 patients with PCa enrolled in this study. Surgery (54%), external radiation (20%), and active surveillance (12%) were the most common primary treatments for patients with low- and intermediate-risk PCa, whereas patients with high-risk PCa chose surgery (34%) or external radiation with neoadjuvant hormones (57%). Treatment choice differed by age at diagnosis, race, comorbidity status, and calendar year in both univariable and multivariable analyses. Patients preferred to play an active role in the decision-making process and cited doctors at the clinic as the most helpful source of treatment-related information. Almost all patients reported satisfaction with their decision. CONCLUSIONS: This is one of the first prospective cohort studies to examine treatment decision-making in an equal-access, multidisciplinary clinic setting. Studies of this cohort would aid in understanding and improving the PCa decision-making process. Published by Elsevier Inc.
Authors: Chad Tang; Karen E Hoffman; Pamela K Allen; Molly Gabel; David Schreiber; Seungtaek Choi; Brian F Chapin; Quynh-Nhu Nguyen; John W Davis; Paul Corn; Christopher Logothetis; John Ward; Steven J Frank; Neema Navai; Sean E McGuire; Mitchell Anscher; Louis Pisters; Curtis A Pettaway; Rachit Kumar; Patrick Linson; Prabhakar Tripuraneni; Jeffrey J Tomaszewski; Ashish B Patel; Mark Augspurger; Deborah A Kuban Journal: Cancer Date: 2019-11-19 Impact factor: 6.860
Authors: Claire Kim; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi Journal: PLoS One Date: 2018-02-05 Impact factor: 3.240
Authors: Xavier Bonfill; Ingrid Arevalo-Rodriguez; Laura Martínez García; Maria Jesús Quintana; Diana Buitrago-Garcia; Diego Lobos Urbina; José Antonio Cordero Journal: Cancer Manag Res Date: 2018-08-02 Impact factor: 3.989
Authors: Margaret Fitch; Kittie Pang; Veronique Ouellet; Carmen Loiselle; Shabbir Alibhai; Simone Chevalier; Darrel E Drachenberg; Antonio Finelli; Jean-Baptiste Lattouf; Simon Sutcliffe; Alan So; Simon Tanguay; Fred Saad; Anne-Marie Mes-Masson Journal: BMC Urol Date: 2017-10-27 Impact factor: 2.264